glp-1 news nov 2025 updates november supply shortage ISPOR 2025: Exploring reasons for discontinuation GLP-1 Drugs Driving Protein Demand – GLP-1 RA How Employers Can Manage GLP-1

Semaglutide attenuates doxorubicin-induced cardiotoxicity by ameliorating [PMID: 38574433] Laboratory literature summary: Semaglutide attenuates doxorubicin-induced cardiotoxicity by ameliorating BNIP3-Mediated mitochondrial dysfunction

It is important to remember that not all GLP-1 medications are expressly licensed for weight loss and that the doses used for weight loss may vary from those used for managing diabetes

The pharmacists mix, change, or combine ingredients to create a customized medication

When someone has a problem on an unregulated peptide and turns up at A&E, the treating doctor often doesn't know what's been taken or in what dose

Unlike classical T1D with almost only hyperglycemia, T2D is just one component of MDS, and is often accompanied by other components of MDS, such as overweight/obesity (preobesity might be a more appropriate term instead of overweight since obesity is not determined only by weight), metabolic dysfunction associated steatotic liver disease (MASLD), dyslipidemia

This provides a "shield" of antioxidant protection for the day ahead